AbbVie’s $10.1 billion Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge, says GlobalData
Following the news that AbbVie has agreed to buy biotech ImmunoGen , the maker of the FDA-approved ovarian cancer treatment Elahere, for $10.1 billion; Israel Stern,...